Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A Stock
Bio-Rad Labs Inc. A shows a slight decrease today, losing -€1.600 (-0.660%) compared to yesterday.
Our community is currently high on Bio-Rad Labs Inc. A with 5 Buy predictions and 0 Sell predictions.
With a target price of 334 € there is a positive potential of 38.94% for Bio-Rad Labs Inc. A compared to the current price of 240.4 €.
Our community identified positive and negative aspects for Bio-Rad Labs Inc. A stock for the coming years. 0 users see the criterium "Revenue growth" as a plus for the Bio-Rad Labs Inc. A stock. On the other hand our users think that "Revenue growth" could be a problem in the future.
Pros and Cons of Bio-Rad Labs Inc. A in the next few years
Pros
?
B****
?
M***** P*******
?
S********** s********
Cons
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Bio-Rad Labs Inc. A vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Bio-Rad Labs Inc. A | -0.660% | 2.341% | 5.300% | 8.094% | -6.786% | -44.455% | -50.535% |
| Neogen Corp. | 1.920% | 1.258% | -16.146% | 3.205% | 30.894% | - | - |
| Haemonetics Corp. | 0.820% | -5.000% | -10.182% | - | -27.883% | - | - |
| CONMED Corp. | -1.960% | -3.774% | -21.134% | -44.865% | -12.571% | -67.447% | -72.432% |
Comments
Bio-Rad Laboratories (NYSE:BIO) had its price target raised by analysts at Citigroup Inc. from $350.00 to $375.00. They now have a "buy" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) had its price target raised by analysts at Royal Bank Of Canada from $387.00 to $409.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for BIO provided by MarketBeat
Bio-Rad Laboratories, Inc. (NYSE: BIO) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for BIO provided by MarketBeat

